Publication | Closed Access

Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia

Hematological MalignancyOncologyHeat ShockAcute Myeloid LeukemiaPharmacologyMyeloid NeoplasiaPharmacotherapyAnti-cancer AgentInhibitor AlvespimycinMedicineCancer ResearchDrug DiscoveryDrug Resistance